The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

Barinov A.A.

Moscow City Oncology Hospital No. 62

Vinogradov I.Yu.

Regional Clinical Oncology Dispensary

Vtorushin S.V.

Siberian State Medical University;
Cancer Research Institute of Tomsk National Research Medical Center

Demidova I.A.

Moscow City Oncology Hospital No. 62

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education

Olyushina E.M.

Russian Medical Academy for Continuous Professional Education

Petrov S.V.

Kazan Medical University

Raskin G.A.

Medical Institute named after Berezin Sergey;
St. Petersburg State University

Savelov N.A.

Moscow City Oncology Hospital No. 62

Skrypnikova K.A.

Russian Medical Academy of Continuous Professional Education

Frank G.A.

Russian Medical Academy of Continuous Professional Education

Quality control of immunohistochemical studies: compulsory duty or urgent need?

Authors:

Zavalishina L.E., Andreeva Yu.Yu., Barinov A.A., Vinogradov I.Yu., Vtorushin S.V., Demidova I.A., Kuznetsova O.A., Olyushina E.M., Petrov S.V., Raskin G.A., Savelov N.A., Skrypnikova K.A., Frank G.A.

More about the authors

Read: 1996 times


To cite this article:

Zavalishina LE, Andreeva YuYu, Barinov AA, et al. Quality control of immunohistochemical studies: compulsory duty or urgent need? Russian Journal of Archive of Pathology. 2025;87(2):43‑52. (In Russ.)
https://doi.org/10.17116/patol20258702143

Recommended articles:
Orga­nization of the HLA-typing labo­ratories. Labo­ratory Service. 2025;(3):26-32
Prognostically unfa­vorable types of breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(6):78-82
Extramammary Paget’s disease. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):726-733

References:

  1. Zavalishina LE, Artem’eva AS, Vtorushin SV, Kuznetsova OA, Leenman EE, Petrov SV, Savelov NA, Vasil’eva AI, Skrypnikova KA, Frank GA. Analysis of the work of the Immunohistochemical Quality Control Center of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia in 2023. Russian Journal of Archive of Pathology. 2024;86(3):38-45. (In Russ.). https://doi.org/10.17116/patol20248603138
  2. The Ministry of Health of the Russian Federation. Clinical recommendations. Breast cancer. 2021. (In Russ.). https://cr.minzdrav.gov.ru/view-cr/379_4
  3. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology-College of American Pathologists Guideline update. Arch Pathol Lab Med. 2023;147(9):993-1000. https://doi.org/10.5858/arpa.2023-0950-SA
  4. Zavalishina LE, Gorban’ NA, Vtorushin SV, Grinevich VN, Demidova IA, Kometova VV, Kudaibergenova AG, Kuznetsova OA, Raskin GA, Tertychnyi AS, Frank GA. Zlokachestvennye opukholi. Rukovodstvo po testirovaniyu HER2-statusa. 2024. 36p. (In Russ.). https://doi.org/10.18027/2224-5057-2024-10e-36
  5. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Klinicheskie rekomendatsii. Zlokachestvennoe novoobrazovanie obodochnoi kishki. 2022. (In Russ.). Available at: https://cr.minzdrav.gov.ru/view-cr/396_3
  6. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Klinicheskie rekomendatsii. Rak tela matki i sarkomy matki. 2024. (In Russ.). https://cr.minzdrav.gov.ru/view-cr/460_4
  7. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Klinicheskie rekomendatsii. Rak mochevogo puzyrya. 2023. (In Russ.). https://cr.minzdrav.gov.ru/view-cr/11_3
  8. Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial. J Clin Oncol. 2024;42(1):47-58.  https://doi.org/10.1200/jco.23.02005

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.